• Je něco špatně v tomto záznamu ?

Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre

M. Lukas, K. Malickova, M. Kolar, M. Bortlik, M. Vasatko, N. Machkova, V. Hruba, D. Duricova, M. Lukas

. 2020 ; 14 (7) : 915-919. [pub] 2020Jul30

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020332

BACKGROUND AND AIMS: Patients' perspectives after switching from originator to biosimilar adalimumab have yet to be assessed. We evaluated the efficacy of switching from the originator adalimumab to a biosimilar compound [SB5] in patients with inflammatory bowel disease [IBD]. METHODS: Data on IBD patients who were switched from the originator to biosimilar adalimumab [SB5] at IBD Center ISCARE were analysed. Disease activity was assessed using standard clinical indices (Harvey-Bradshaw index [HBI] for Crohn's disease [CD] and partial Mayo score for ulcerative colitis [UC]), and laboratory parameters (C-reactive protein [CRP] and faecal calprotectin [FC]). Trough levels and anti-drug antibodies were measured. Patients were evaluated 10 weeks [W10] after the switch, and results were compared with the control group of patients on originator compound. RESULTS: A total of 93 patients switched to biosimilar adalimumab were included [CD 86%] and were matched to 93 controls for age, gender, diagnosis, and disease activity. There was no difference in the disease activity in either SWITCH or ORIGINATOR cohorts between Weeks 0 and 10. Similarly, no difference was found between cohorts at both prespecified time points. Moreover, no significant differences in CRP or FC concentrations were seen between W0 and W10 either in the SWITCH, or in the ORIGINATOR cohort [p >0.05]. Adalimumab serum trough levels remained stable after the switch. No new safety signals were detected. CONCLUSIONS: Our study confirmed that switching IBD patients from the originator adalimumab to a biosimilar compound [SB5] does not affect treatment efficacy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020332
003      
CZ-PrNML
005      
20210830102043.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjaa001 $2 doi
035    __
$a (PubMed)31905382
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Lukas, Martin $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic
245    10
$a Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre / $c M. Lukas, K. Malickova, M. Kolar, M. Bortlik, M. Vasatko, N. Machkova, V. Hruba, D. Duricova, M. Lukas
520    9_
$a BACKGROUND AND AIMS: Patients' perspectives after switching from originator to biosimilar adalimumab have yet to be assessed. We evaluated the efficacy of switching from the originator adalimumab to a biosimilar compound [SB5] in patients with inflammatory bowel disease [IBD]. METHODS: Data on IBD patients who were switched from the originator to biosimilar adalimumab [SB5] at IBD Center ISCARE were analysed. Disease activity was assessed using standard clinical indices (Harvey-Bradshaw index [HBI] for Crohn's disease [CD] and partial Mayo score for ulcerative colitis [UC]), and laboratory parameters (C-reactive protein [CRP] and faecal calprotectin [FC]). Trough levels and anti-drug antibodies were measured. Patients were evaluated 10 weeks [W10] after the switch, and results were compared with the control group of patients on originator compound. RESULTS: A total of 93 patients switched to biosimilar adalimumab were included [CD 86%] and were matched to 93 controls for age, gender, diagnosis, and disease activity. There was no difference in the disease activity in either SWITCH or ORIGINATOR cohorts between Weeks 0 and 10. Similarly, no difference was found between cohorts at both prespecified time points. Moreover, no significant differences in CRP or FC concentrations were seen between W0 and W10 either in the SWITCH, or in the ORIGINATOR cohort [p >0.05]. Adalimumab serum trough levels remained stable after the switch. No new safety signals were detected. CONCLUSIONS: Our study confirmed that switching IBD patients from the originator adalimumab to a biosimilar compound [SB5] does not affect treatment efficacy.
650    _2
$a adalimumab $x krev $x imunologie $x terapeutické užití $7 D000068879
650    _2
$a dospělí $7 D000328
650    _2
$a protilátky $x krev $7 D000906
650    _2
$a biosimilární léčivé přípravky $x krev $x terapeutické užití $7 D059451
650    _2
$a C-reaktivní protein $x metabolismus $7 D002097
650    _2
$a ulcerózní kolitida $x krev $x farmakoterapie $7 D003093
650    _2
$a Crohnova nemoc $x krev $x farmakoterapie $7 D003424
650    _2
$a náhrada léků $7 D057915
650    _2
$a feces $x chemie $7 D005243
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gastrointestinální látky $x krev $x imunologie $x terapeutické užití $7 D005765
650    _2
$a lidé $7 D006801
650    _2
$a leukocytární L1-antigenní komplex $x analýza $7 D039841
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a centra terciární péče $7 D062606
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Malickova, K $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kolar, M $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic
700    1_
$a Bortlik, M $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic $u Department of Internal Medicine, Military University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vasatko, M $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic
700    1_
$a Machkova, N $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic
700    1_
$a Hruba, V $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic
700    1_
$a Duricova, D $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Lukas, Milan $u Clinical and Research Centre for Inflammatory Bowel Disease, ISCARE, Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00166945 $t Journal of Crohn's & colitis $x 1876-4479 $g Roč. 14, č. 7 (2020), s. 915-919
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31905382 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102043 $b ABA008
999    __
$a ok $b bmc $g 1691001 $s 1140778
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 14 $c 7 $d 915-919 $e 2020Jul30 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace